INTRASITE VANCOMYCIN POWDER AS A PROPHYLACTIC ADJUVANT IN LUMBAR FUSION

ABSTRACT Objective: To identify whether the use of prophylactic intrasite vancomycin as an adjuvant is a protective factor against deep tissue infection of the surgical site. Methods: Retrospective, descriptive, case-control study evaluating 210 patients, of whom 70 received intrasite vancomycin...

Full description

Bibliographic Details
Main Authors: Jorge Álvaro González Ross, Alfredo Javier Moheno Gallardo, Eulalio Elizalde Martínez, José Manuel Pérez Atanasio, Ruth Martínez Martínez
Format: Article
Language:English
Published: Sociedade Brasileira de Coluna (SBC) 2016-03-01
Series:Coluna/Columna
Subjects:
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1808-18512016000100044&lng=en&tlng=en
id doaj-612f455491b04499bdda294b203b6e56
record_format Article
spelling doaj-612f455491b04499bdda294b203b6e562020-11-25T00:21:09ZengSociedade Brasileira de Coluna (SBC)Coluna/Columna 2177-014X2016-03-01151444710.1590/S1808-185120161501154501S1808-18512016000100044INTRASITE VANCOMYCIN POWDER AS A PROPHYLACTIC ADJUVANT IN LUMBAR FUSIONJorge Álvaro González RossAlfredo Javier Moheno GallardoEulalio Elizalde MartínezJosé Manuel Pérez AtanasioRuth Martínez MartínezABSTRACT Objective: To identify whether the use of prophylactic intrasite vancomycin as an adjuvant is a protective factor against deep tissue infection of the surgical site. Methods: Retrospective, descriptive, case-control study evaluating 210 patients, of whom 70 received intrasite vancomycin (case group) and 140 were controls. It was made a follow up for at least one year, reviewing the physical and electronic records. Data were tabulated in spreadsheets (Excel) including all variables and the statistical analysis was made with Epi InfoTM 7 to calculate the odds ratio. Results: Seven cases of deep infection occurred in the control group and none was found in the case group (odds ratio [95% confidence interval]: 0.1262 [0.007-2.24], P = 0.1585). Among the predisposing factors, diabetes and surgical time were the most relevant. Conclusions: Intrasite use of vancomycin has a protective effect against deep infection in patients undergoing lumbar fusion surgery without presenting considerable side effects.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1808-18512016000100044&lng=en&tlng=enVancomicinaFusión vertebralInfección de herida operatoriaProfilaxis antibiótica
collection DOAJ
language English
format Article
sources DOAJ
author Jorge Álvaro González Ross
Alfredo Javier Moheno Gallardo
Eulalio Elizalde Martínez
José Manuel Pérez Atanasio
Ruth Martínez Martínez
spellingShingle Jorge Álvaro González Ross
Alfredo Javier Moheno Gallardo
Eulalio Elizalde Martínez
José Manuel Pérez Atanasio
Ruth Martínez Martínez
INTRASITE VANCOMYCIN POWDER AS A PROPHYLACTIC ADJUVANT IN LUMBAR FUSION
Coluna/Columna
Vancomicina
Fusión vertebral
Infección de herida operatoria
Profilaxis antibiótica
author_facet Jorge Álvaro González Ross
Alfredo Javier Moheno Gallardo
Eulalio Elizalde Martínez
José Manuel Pérez Atanasio
Ruth Martínez Martínez
author_sort Jorge Álvaro González Ross
title INTRASITE VANCOMYCIN POWDER AS A PROPHYLACTIC ADJUVANT IN LUMBAR FUSION
title_short INTRASITE VANCOMYCIN POWDER AS A PROPHYLACTIC ADJUVANT IN LUMBAR FUSION
title_full INTRASITE VANCOMYCIN POWDER AS A PROPHYLACTIC ADJUVANT IN LUMBAR FUSION
title_fullStr INTRASITE VANCOMYCIN POWDER AS A PROPHYLACTIC ADJUVANT IN LUMBAR FUSION
title_full_unstemmed INTRASITE VANCOMYCIN POWDER AS A PROPHYLACTIC ADJUVANT IN LUMBAR FUSION
title_sort intrasite vancomycin powder as a prophylactic adjuvant in lumbar fusion
publisher Sociedade Brasileira de Coluna (SBC)
series Coluna/Columna
issn 2177-014X
publishDate 2016-03-01
description ABSTRACT Objective: To identify whether the use of prophylactic intrasite vancomycin as an adjuvant is a protective factor against deep tissue infection of the surgical site. Methods: Retrospective, descriptive, case-control study evaluating 210 patients, of whom 70 received intrasite vancomycin (case group) and 140 were controls. It was made a follow up for at least one year, reviewing the physical and electronic records. Data were tabulated in spreadsheets (Excel) including all variables and the statistical analysis was made with Epi InfoTM 7 to calculate the odds ratio. Results: Seven cases of deep infection occurred in the control group and none was found in the case group (odds ratio [95% confidence interval]: 0.1262 [0.007-2.24], P = 0.1585). Among the predisposing factors, diabetes and surgical time were the most relevant. Conclusions: Intrasite use of vancomycin has a protective effect against deep infection in patients undergoing lumbar fusion surgery without presenting considerable side effects.
topic Vancomicina
Fusión vertebral
Infección de herida operatoria
Profilaxis antibiótica
url http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1808-18512016000100044&lng=en&tlng=en
work_keys_str_mv AT jorgealvarogonzalezross intrasitevancomycinpowderasaprophylacticadjuvantinlumbarfusion
AT alfredojaviermohenogallardo intrasitevancomycinpowderasaprophylacticadjuvantinlumbarfusion
AT eulalioelizaldemartinez intrasitevancomycinpowderasaprophylacticadjuvantinlumbarfusion
AT josemanuelperezatanasio intrasitevancomycinpowderasaprophylacticadjuvantinlumbarfusion
AT ruthmartinezmartinez intrasitevancomycinpowderasaprophylacticadjuvantinlumbarfusion
_version_ 1725363671963533312